Teva Pharmaceutical Industries Limited (TEVA) Q4 2019 Earnings Call Transcript

Teva Pharmaceutical Industries Limited (TEVA) Q4 2019 Earnings Call Transcript

[Technical Issues] discuss Teva's fourth quarter and full year 2019 financial results.. Our Chief Financial Officer, Eli Kalif will follow-up by reviewing the fourth quarter financial results in more detail before providing an overview of Teva's 2020 financial outlook.. Alone in the U.S., we had nearly 50 launches including our first big biosimilar launch in the U.S.. If we move to the next slide, then you probably all remember that in 2017, so a bit more than two years ago, 2.5 years ago, we had a pretty dramatic situation.. We are still fully operational on all the many, many products we do, 30,000 different products; many, many billions of SKUs per year.. If we move to the next slide, then I'd like to address the gross margin improvement program that we just initiated and that we'll be running over the coming years.. Now in the coming years, we will also be very focused on optimizing each and every manufacturing site for better efficiency, better ratio between output and costs and we are very convinced that this is something we can do successfully.. Given the fact that we still have around 60 manufacturing sites worldwide and we sell billions of products